References
- Al-Ghananeem AM, Saeed H, Florence R, et al. (2010). Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting: an attractive route against infections caused by aids viruses. J Drug Target 18:381–8
- Alpesh M, Snjezana S, Lisbeth I. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57
- Bram S, Suzanne B, Chantal K, et al. (2010). Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 28:6282–91
- Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 336:367–75
- Calvo P, Remunan-Lopez C, Vila-Jato JL, et al. (1997). Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125–32
- Chai GB, Fan YF, Li FZ. (2009). Effect of borneol/mentholum eutectic mixture on nasal-brain delivery of neurotoxin loaded nanoparticles. China J Chi Mater Med 34:698–701
- Feng S, Huang G. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71:53–69
- Gao XL, Tao WX, Lu W, et al. (2006). Lectin-conjugated PEG–PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 27:3482–90
- Govender T, Stolnik S, Garnett MC, et al. (1999). PLGA nanoparticles preparation by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57:171–85
- Graff CL, Pollack GM. (2005). Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94:1187–95
- Jing YS. (1994). New nootropics aniracetam. World Pharm 15:327–40
- Kreuter J. (2001). Nanoparticulate system for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81
- Lee CR, Benfield P. (1994). Aniracetam. Drugs Aging 4:257–73
- Lehr CM, Boustra JA, Schacht EH, et al. (1992). In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 78:43–8
- Li Y-P, Pei Y-Y, Zhang X-Y, et al. (2001). PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation, and biodistribution in rats. J Control Release 71:203–11
- Li XM, Xu YL, Chen GG, et al. (2008). PLGA Nanoparticles for the oral delivery of 5-fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies. Drug Dev Ind Pharm 34:107–15
- Muthu MS, Rawat MK, Mishra A. (2009). PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine 5:323–33
- Olivier J-C. (2005). Drug transport to brain with targeted nanoparticles. Blood-Brain Barrier Neurother 2:108–19
- Patil YB, Toti US, Khdair A, et al. (2009). Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 30:859–66
- Roncari G. (1993). Human pharmacokinetics of aniracetam. Drug Invest 5:68–72
- Seju U, Kumar A, Sawant KK. (2011). Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 7:4169–76
- Shah N, Chaudhari K, Dantuluri P, et al. (2009). Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 17:533–42
- Tobío M, Sánchez A, Vila A, et al. (2000). The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surf B 18:315–23
- Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 70:735–40
- Xu L, Sun Y, Xu P, et al. (2007). Assay of levodopa in brain by CE. Artif Cells Nanomed Biotechnol 35:415–20
- Zhang QZ, Wang MN, Cao SL, et al. (2006). Preparation of chitosan-coated PLA nanoparticles for intranasal delivery and evaluation on its brain targeting efficiency. Chin Pharm Assoc 1:25–49